"GeoArea_Code","GeoArea_Desc","ISO3CD","X","Y","GoalCode","GoalDesc","TargetCode","TargetDesc","IndicatorCode","IndicatorDesc","IndicatorTier","SeriesCode","SeriesDesc","SeriesRelease","Units_Code","Units_Desc","ReportingType_Code","ReportingType_Desc","Value_2000","Value_2001","Value_2002","Value_2003","Value_2004","Value_2005","Value_2006","Value_2007","Value_2008","Value_2009","Value_2010","Value_2011","Value_2012","Value_2013","Value_2014","Value_2015","Value_2016","Latest_Year","Latest_Value","Nature_Desc","Source"
"4","Afghanistan","AFG","66.02688198","33.83160199","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","2","9","18","4","23","24","29","31","33","35","39","39","39",2016.0,"39","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"8","Albania","ALB","20.06660928","41.13897007","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","90","93","93","96","97","94","95","98","98","98","99","99","99","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"10","Antarctica","ATA","21.47585697","-80.40897662","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"12","Algeria","DZA","2.678164227","28.15940032","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","78","73","93","96","94","94","98","95","96","98","95","96","95","93","99","99","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"16","American Samoa","ASM","-170.7187269","-14.30587306","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"20","Andorra","AND","1.576257417","42.54548611","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","80","86","82","86","82","89","91","90","88","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"24","Angola","AGO","17.57817062","-12.33724746","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","26","26",2016.0,"26","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"28","Antigua and Barbuda","ATG","-61.7999755","17.07761471","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","46","68","78","83","94","92","89","90","87","87","87","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"31","Azerbaijan","AZE","50.01064725","40.39229544","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","65","67","66","67","67","68","75","79","83","89","92","95","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"32","Argentina","ARG","-65.14563274","-35.19446255","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","56","56","83","80","93","88","91","84","88","96","94","91","89","83","96","87","88",2016.0,"88","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"36","Australia","AUS","134.3499412","-25.57717202","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","85","85","87","89","80","82","88","90","91","92","93","93","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"40","Austria","AUT","14.14172472","47.58704857","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","35","34","39","46","47","54","61","56","62","64","69","73","78","82","87","88","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"44","Bahamas","BHS","-78.05111663","24.69546597","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","95","88","88","84","80","76","78","79","73","69","72","76","74",2016.0,"74","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"48","Bahrain","BHR","50.5490754","26.04407747","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","92","99","97","99","99","99","99","99","97","99","98","98","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"50","Bangladesh","BGD","89.17660788","22.86961622","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","35","70","83","83","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"51","Armenia","ARM","44.93839317","40.29499741","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","96","95","93","94","92","85","93","94","96","97","98","97","97","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"52","Barbados","BRB","-59.5346489","13.13648273","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","12","41","71","99","98","94","96","97","97","96","94","90","89","91","89","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"56","Belgium","BEL","4.660976456","50.64104975","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","78","78","81","83","83","83","85","85","85","85","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"60","Bermuda","BMU","-64.78155012","32.27881922","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"64","Bhutan","BTN","90.45098484","27.39598568","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","72","79","85","95","90","89","92","94","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"68","Bolivia (Plurinational State of)","BOL","-64.66224284","-16.71273412","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"70","Bosnia and Herzegovina","BIH","17.78584332","44.16845548","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","74","86","90","85","88","90","93","95","92","88","91","88","94","93","92","88","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"72","Botswana","BWA","23.81380223","-22.18810073","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","83","85","80","74",2016.0,"74","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"74","Bouvet Island","BVT","3.410732868","-54.43295905","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"76","Brazil","BRA","-53.08432878","-10.77668561","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","95","80","74","68","61","55","49","56","55","53","71","70","69","89","80","72",2016.0,"72","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"84","Belize","BLZ","-88.70199554","17.19965901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","87","92","89","90","92","91","98","93","92","92","95","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"86","British Indian Ocean Territory","IOT","72.38715553","-7.299281071","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"90","Solomon Islands","SLB","160.1584117","-9.622391719","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"92","British Virgin Islands","VGB","-64.63294223","18.42256578","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"96","Brunei Darussalam","BRN","114.6288563","4.49736984","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","95","96","96","97","95","94","92","90","99","93","93","92","92","96","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"100","Bulgaria","BGR","25.23763153","42.75731323","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","83","85","79","89","91","92","93","94","94","93","96","94","94","94","89","87","88",2016.0,"88","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"104","Myanmar","MMR","96.51752295","21.19332882","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","57","65","75","80","","80","82","78","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"108","Burundi","BDI","29.89080992","-3.366387428","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","51","60","65","72",2016.0,"72","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"112","Belarus","BLR","28.04940161","53.54193075","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","92","97","98","98","98","98","95","99","99","99","99","99","97","99","98","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"116","Cambodia","KHM","104.922836","12.71163737","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","41","49","59","58","58",2016.0,"58","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"120","Cameroon","CMR","12.7419827","5.692387031","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"124","Canada","CAN","-101.6575058","57.72360191","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","94","92","90","88","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"132","Cabo Verde","CPV","-23.63544151","15.07791834","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","99","94","89","79","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"136","Cayman Islands","CYM","-81.16740559","19.32266656","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"140","Central African Republic","CAF","20.93559492","7.003720791","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"144","Sri Lanka","LKA","80.70489654","7.614693343","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","52","92","90","95","99","98","97","97","97","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"148","Chad","TCD","18.66618401","15.36279341","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"152","Chile","CHL","-71.23029019","-35.2652885","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","96","96","95","95","89","89","84","77","74","78","88","89","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"156","China","CHN","104.1403375","32.30955217","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","84","94","92","95","98","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"162","Christmas Island","CXR","105.6426067","-10.4882473","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"166","Cocos (Keeling) Islands","CCK","96.82633757","-12.18600682","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"170","Colombia","COL","-73.07446751","3.888209046","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","84","83","93","70","70","73","85","93","70","71","74","76","80","72","88","86","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"174","Comoros","COM","43.34234565","-11.66121732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"175","Mayotte","MYT","45.14015057","-12.82217691","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"178","Congo","COG","15.22052612","-0.840544119","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"180","Democratic Republic of the Congo","COD","23.65496507","-2.877154732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"184","Cook Islands","COK","-159.7711391","-21.22696458","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","70","50","61","88","86","97","99","98","95","61","98","96","98","95","98","95","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"188","Costa Rica","CRI","-84.19712782","9.970998683","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","89","84","79","80","95","92","90","90","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"191","Croatia","HRV","17.95874553","45.45172212","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","98","98","98","98","98","98","98","98","98","98","98","97","97","97","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"192","Cuba","CUB","-79.54460144","22.10030366","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","53","97","99","98","95","98","95","96","97","98","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"196","Cyprus","CYP","33.22285964","35.05659437","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","93","89","88","88","88","88","88","88","88","88",2016.0,"88","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"203","Czechia","CZE","15.33151382","49.73913871","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","98","98","98","98","98","98","98","98","98","98","98","99","99","96","99","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"204","Benin","BEN","2.339933594","9.65401646","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"208","Denmark","DNK","9.326571283","56.03829721","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","87","92","88","88","91","91","88","87","85","85","86","87","86","84","80","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"212","Dominica","DMA","-61.3493756","15.43391378","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","62","99","99","99","99","99","95","95","95","95","94","94","91","89","94","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"214","Dominican Republic","DOM","-70.49847576","18.89832088","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"218","Ecuador","ECU","-78.37005241","-1.447785891","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","99","91","92","81","70","59","76","76",2016.0,"76","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"222","El Salvador","SLV","-88.86862995","13.73603564","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","77","80","85","89","86","79","82","78","81","95","85","85","88","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"226","Equatorial Guinea","GNQ","10.46535826","1.565792376","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"231","Ethiopia","ETH","39.63505296","8.631223181","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"232","Eritrea","ERI","38.11074289","16.12894644","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","75","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"233","Estonia","EST","25.84093481","58.68487172","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","89","84","94","96","97","98","98","96","97","96","95","95","94","92","93","92","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"234","Faroe Islands","FRO","-7.122044325","62.21228119","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"238","Falkland Islands (Malvinas)","FLK","-58.75246778","-51.74562601","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"239","South Georgia and the South Sandwich Islands","SGS","-36.90662765","-54.20736749","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"242","Fiji","FJI","177.9660884","-17.83301566","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","74","94","94","94","94","94","94","94","94","94","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"246","Finland","FIN","23.308447","61.91586738","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"248","land Islands","ALA","19.80945969","60.1544901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"250","France","FRA","2.457288129","46.62660861","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","67","67","72","67","77","78","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"254","French Guiana","GUF","-53.23619089","3.922673437","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"258","French Polynesia","PYF","-149.4052367","-17.67709294","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"260","French Southern Territories","ATF","69.64849091","-49.6068576","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"262","Djibouti","DJI","42.18274707","11.56004161","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","82","82","82","82","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"266","Gabon","GAB","11.78727747","-0.60687619","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"268","Georgia","GEO","43.3713615","42.04813028","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","8","40","57","75","87","88","92","87","71","84","77","79","89","87","91","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"270","Gambia","GMB","-15.39944785","13.45295927","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","56","53","73","81","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"275","State of Palestine","PSE","35.25694122","31.94347933","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","94","93","94","94","97","92","87","99","97","94","95","97","98","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"276","Germany","DEU","10.3806066","51.08862743","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","77","83","89","91","90","92","92","93","93","93","93","93","93","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"288","Ghana","GHA","-1.205623522","7.964825185","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","52","54","67","63","75",2016.0,"75","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"292","Gibraltar","GIB","-5.347561686","36.13895036","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"296","Kiribati","KIR","-157.5643005","1.768837732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","35","21","61","9","84","80","76","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"300","Greece","GRC","22.58307827","39.47301873","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","77","77","77","77","77","83","83","83","83","83",2016.0,"83","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"304","Greenland","GRL","-41.39371316","74.75625681","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"308","Grenada","GRD","-61.68248568","12.11238395","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","74","68","61","81","87","86","86","78","86","85","75","85","92","89","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"312","Guadeloupe","GLP","-61.64762115","16.14416917","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"316","Guam","GUM","144.7029305","13.35485404","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"320","Guatemala","GTM","-91.2312746","15.00273719","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","65",2016.0,"65","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"324","Guinea","GIN","-11.28173419","11.00210343","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"328","Guyana","GUY","-58.97322037","4.788012784","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","88","80","71","63","72","74","90","84","84","82","84","90","95","91","95","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"332","Haiti","HTI","-72.33640958","18.40426539","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","26",2016.0,"26","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"334","Heard Island and McDonald Islands","HMD","73.52633626","-53.09106147","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"336","Holy See","VAT","12.45315803","41.90343751","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"340","Honduras","HND","-86.59974381","14.82243161","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"344","China, Hong Kong Special Administrative Region","HKG","114.0266445","22.41749934","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"348","Hungary","HUN","19.41221519","47.1651448","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","99","99","99","99","99","99","99","96","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"352","Iceland","ISL","-19.02116966","64.79134763","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","92","89","90","93","95","94","93","92","90","97","94","93","94","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"356","India","IND","79.3608464","22.34642074","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","27","36","51","60","69","76",2016.0,"76","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"360","Indonesia","IDN","113.9174","-0.994582204","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","21","29","23","50","73","66","67","74","76","78","76","28","31","56",2016.0,"56","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"364","Iran (Islamic Republic of)","IRN","54.19766348","32.74370885","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","94","96","96","99","92","98","97","96","99","99","99","97","97","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"368","Iraq","IRQ","43.76606267","33.05013795","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","52","48","45","41","58","52","64","76","87","77","77","68","57","60","62","64",2016.0,"64","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"372","Ireland","IRL","-7.121425272","53.25274054","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"376","Israel","ISR","34.62277992","31.06164552","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","97","97","97","97","96","96","90","91","92","93","87","89","95","96","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"380","Italy","ITA","12.57022427","42.79917282","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","84","83","83","83",2016.0,"83","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"384","Cte d'Ivoire","CIV","-5.552690016","7.62211586","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"388","Jamaica","JAM","-77.31068409","18.15616857","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","96","96","95","95","91","88","84","80","78","56","60","76","71","72","83","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"392","Japan","JPN","139.2716103","36.6554539","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","78","92","97","92","92","93","94","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"398","Kazakhstan","KAZ","66.65359159","48.01963494","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","95","98","99","99","96","99","99","99","99","99","99","97","99","99","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"400","Jordan","JOR","37.13024774","30.65365973","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","83","87","90","91","98","92","88","97","90","90","95","95","96","98","98","96","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"404","Kenya","KEN","37.86096816","0.534797278","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","28","32",2016.0,"32","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"408","Democratic People's Republic of Korea","PRK","127.1803633","40.1462645","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","98","98","99","99","99","99","99","97","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"410","Republic of Korea","KOR","127.8610254","36.45201023","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","39","67","95","95","99","99","99","99","99","99","98","98","97","95","96","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"414","Kuwait","KWT","47.49305029","29.53949468","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","77","96","90","86","94","99","99","99","99","86","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"417","Kyrgyzstan","KGZ","74.52324839","41.46204516","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","98","98","98","98","98","97","95","97","98","98","98","98","97","97","96","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"418","Lao People's Democratic Republic","LAO","101.9901968","20.27482773","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"422","Lebanon","LBN","35.89391711","33.92152458","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","56","42","28","14","24","34","45","55","65","75","75","75","75","75","75","75","75",2016.0,"75","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"426","Lesotho","LSO","28.25362195","-29.58041814","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","46","50","47","56","68","80","80","80","81","81","82","82","82","82","82","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"428","Latvia","LVA","26.42461876","56.64196636","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","95","96","97","98","99","99","98","94","92","93","92","92","92","89","92","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"430","Liberia","LBR","-9.311879038","6.448381009","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"434","Libya","LBY","18.0295985","27.04042819","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","81","86","90","95","95","96","97","97","97","97","97","97","95","92","97","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"438","Liechtenstein","LIE","9.552985019","47.14167005","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"440","Lithuania","LTU","23.90517807","55.33680309","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","96","95","93","93","95","94","96","96","94","95","94","93","92","92","92","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"442","Luxembourg","LUX","6.092656563","49.77679538","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","86","86","86","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"446","China, Macao Special Administrative Region","MAC","113.5665388","22.1237259","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"450","Madagascar","MDG","46.6982339","-19.38514785","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"454","Malawi","MWI","33.4884625","-13.40819859","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","8","61",2016.0,"61","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"458","Malaysia","MYS","116.8346314","5.452415309","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","91","90","92","97","95","95","95","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"462","Maldives","MDV","73.09672546","-0.614385021","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","56","76","96","96","96","99","99","97","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"466","Mali","MLI","-3.522016039","17.35311254","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"470","Malta","MLT","14.44617519","35.89194275","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","2","31","60","86","77","83","85","85","85","91","88","94","91","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"474","Martinique","MTQ","-60.91544135","14.56086108","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"478","Mauritania","MRT","-10.33187259","20.26089546","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"480","Mauritius","MUS","57.568022","-20.28581998","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","80","78","85","80","83","85","90","89","90","85","85","96","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"484","Mexico","MEX","-102.5148166","23.93378032","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","99","89","96","97","97","91","85","94","92","91","97","92","76","95","96","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"492","Monaco","MCO","7.424214814","43.73532918","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"496","Mongolia","MNG","103.0728057","46.83892054","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","75","95","96","98","98","98","96","97","96","97","95","98","98","97","98","98","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"498","Republic of Moldova","MDA","28.4650624","47.20236795","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","69","96","98","98","99","95","97","98","98","96","95","94","93","90","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"499","Montenegro","MNE","19.25214024","42.78717043","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","95","96","96","97","97","97","94","95","94","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"500","Montserrat","MSR","-62.19261223","16.73558313","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"504","Morocco","MAR","-6.281942841","31.8440131","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","91","92","92","92","","","","","","","54","95","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"508","Mozambique","MOZ","38.18479941","-14.27963886","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","51",2016.0,"51","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"512","Oman","OMN","57.87743482","21.98805614","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","98","98","98","97","97","95","98","99","99","99","99","99","99","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"516","Namibia","NAM","17.21907885","-22.13817068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"520","Nauru","NRU","166.92313","-0.528742623","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","95","83","72","60","50","97","99","99","92","99","99","81","88","94","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"524","Nepal","NPL","83.94678863","28.25866332","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","25",2016.0,"25","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"528","Netherlands","NLD","5.331480568","51.86728884","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","96","98","98","93","92","92","93","93","92","93","93","92","93","92","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"530","Netherlands Antilles","ANT","-68.30676179","12.22720635","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"531","Curaao","CUW","-68.95033464","12.15058042","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"533","Aruba","ABW","-69.97050586","12.50878756","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"534","Sint Maarten (Dutch part)","SXM","-63.06198692","18.03926508","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"540","New Caledonia","NCL","165.5067368","-21.41742531","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"548","Vanuatu","VUT","167.0679779","-15.34445547","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"554","New Zealand","NZL","170.4755673","-43.98721568","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","86","85","86","86","87","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"558","Nicaragua","NIC","-85.03060315","12.84210839","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"562","Niger","NER","9.400167877","17.42143036","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","3","16","37",2016.0,"37","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"566","Nigeria","NGA","8.097363256","9.585789025","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"570","Niue","NIU","-169.8601693","-19.05000475","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","90","86","99","70","99","99","99","99","99","98","98","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"574","Norfolk Island","NFK","167.9515548","-29.03230018","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"578","Norway","NOR","11.47846389","61.34311134","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","90","90","89","90","91","91","93","95","96","97","94","91","91","92","91","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"580","Northern Mariana Islands","MNP","145.7582114","15.19099517","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"581","US Minor Outlying Islands","UMI","-162.4343752","5.874443968","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"583","Micronesia, Federated States of","FSM","158.225216","6.880670092","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"583","Micronesia (Federated States of)","FSM","158.225216","6.880670092","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","50","64","65","66","74","84","85","86","84","82","75","75","70","75","75","74","74",2016.0,"74","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"584","Marshall Islands","MHL","171.0839119","7.110213497","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","6","6","70","90","92","71","60","91","79","66","90","74","58","56","53","70","49",2016.0,"49","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"585","Palau","PLW","134.5733878","7.502307591","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","75","83","90","94","98","95","98","83","77","79","39","83","86","98","81","82","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"586","Pakistan","PAK","68.80479684","29.36491634","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","30","51","53","53","53","53","53","53",2016.0,"53","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"591","Panama","PAN","-81.26616623","8.450965746","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","88","88","88","89","89","89","86","83","79","76","73","81","72","68","90","92","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"598","Papua New Guinea","PNG","145.8587761","-6.756057077","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"600","Paraguay","PRY","-60.54854225","-21.70216237","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","31","61","74","84","80","81","82","79","81","81","77","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"604","Peru","PER","-71.82093277","-13.58939705","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","9","17","42","56","70","63","54","44","63","66",2016.0,"66","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"608","Philippines","PHL","120.8601418","14.16591706","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","19","10","36","42","54","59","67","66",2016.0,"66","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"612","Pitcairn","PCN","-128.3225873","-24.37538456","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"616","Poland","POL","19.40660158","52.1226733","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","96","97","97","96","90","99","98","97","95","94","95","95","93","95","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"620","Portugal","PRT","-7.961599811","39.68509315","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","48","56","64","72","79","87","95","95","95","95","95","96","96","96","96","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"624","Guinea-Bissau","GNB","-14.40182514","12.11760394","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"626","Timor-Leste","TLS","125.9451052","-8.797497247","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","22",2016.0,"22","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"630","Puerto Rico","PRI","-66.47591017","18.22753799","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"634","Qatar","QAT","51.19152467","25.28355379","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","91","91","95","98","87","91","95","99","98","99","99","99","95","91","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"638","Runion","REU","55.53171398","-21.13183266","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"642","Romania","ROU","24.98481009","45.83893563","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","97","97","97","96","96","96","96","95","94","93","91","90","88","84","80","76",2016.0,"76","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"643","Russian Federation","RUS","99.01404926","61.61899849","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","88","93","96","97","97","97","97","97","97","98","97","97","97","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"646","Rwanda","RWA","29.92310194","-1.999842114","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","87","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"652","Saint Barthlemy","BLM","-62.83173536","17.89513362","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"654","Saint Helena","SHN","-5.705752501","-15.96503946","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"659","Saint Kitts and Nevis","KNA","-62.76628613","17.33994219","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","98","98","97","96","95","94","99","99","99","90","94","90","90","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"660","Anguilla","AIA","-63.05651612","18.21525315","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"662","Saint Lucia","LCA","-60.96529553","13.89405601","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","89","73","71","69","67","56","45","33","22","63","74","72","80","62","79","95","88",2016.0,"88","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"663","Saint Martin (French Part)","MAF","-63.04505461","18.0882685","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"666","Saint Pierre and Miquelon","SPM","-56.33682442","46.85812735","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"670","Saint Vincent and the Grenadines","VCT","-61.19024321","13.24627968","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","99","99","86","73","93","88","83","94","94","89","91","92","96","98","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"674","San Marino","SMR","12.46329038","43.93841766","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","96","96","94","93","91","89","88","86","84","88","77","76","82","36",2016.0,"36","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"678","Sao Tome and Principe","STP","6.609772265","0.241554875","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","71","76","76",2016.0,"76","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"682","Saudi Arabia","SAU","44.54763347","24.12594211","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","96","96","97","97","97","97","98","98","98","98","97","98","99","98","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"686","Senegal","SEN","-14.46636926","14.35920905","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","13","54","75",2016.0,"75","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"688","Serbia","SRB","20.805876","44.03145697","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","78","74","75","96","96","98","90","96","97","87","91","90","90","82","91","86","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"690","Seychelles","SYC","55.46561591","-4.678053059","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","98","99","99","99","99","99","99","98","99","98","99","99","97","98","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"694","Sierra Leone","SLE","-11.78306584","8.568604164","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","60","50",2016.0,"50","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"702","Singapore","SGP","103.8107883","1.361009155","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","96","96","96","96","95","96","96","96","95","95","96","90","90","90","90","88",2016.0,"88","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"703","Slovakia","SVK","19.48495604","48.70741446","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","99","98","98","99","98","99","99","99","99","99","99","98","98","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"704","Viet Nam","VNM","105.802499","10.09643079","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","18","97","96","98","93","83","86","94","92","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"705","Slovenia","SVN","14.82209486","46.11958061","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","98","98","98","99","99","99","98","98","98","96","96","96","95","94","96","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"706","Somalia","SOM","46.20367477","4.406485729","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"710","South Africa","ZAF","24.67184355","-29.99957544","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","62","54","46","52","51","49","55","52","57","66","59","58","59","56","62","66","70",2016.0,"70","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"716","Zimbabwe","ZWE","29.86909584","-19.00075492","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","63",2016.0,"63","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"724","Spain","ESP","-3.554078296","40.39211472","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","91","92","94","95","94","90","92","91","90","91","93","94","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"728","South Sudan","SSD","30.32618773","7.290839152","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"732","Western Sahara","ESH","-13.13515523","24.66265342","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"736","Sudan","SDN","29.95650159","16.02643066","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"740","Suriname","SUR","-55.90626394","4.132603197","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","18","18","28","44",2016.0,"44","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"744","Svalbard and Jan Mayen Islands","SJM","13.38071013","78.82894131","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"748","Eswatini","SWZ","31.50149288","-26.56471011","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","99","99","99","99","99","99","99","99","99","92","52","89","89","89","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"752","Sweden","SWE","14.3775338","60.60103109","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","94","94","95","95","95","95","95","94","95","94","95","95","95","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"756","Switzerland","CHE","8.223158","46.96617097","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","71","71","71","83","83","83","86","86","86","87","89","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"760","Syrian Arab Republic","SYR","38.50466565","35.01676176","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","80","83","84","83","82","81","81","81","81","82","82","71","53","51","49","47","52",2016.0,"52","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"762","Tajikistan","TJK","69.294998","38.43069666","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","59","72","93","94","98","92","96","90","87","93","95","96","97","92","98","94","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"764","Thailand","THA","101.0202951","15.13089239","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","86","89","92","95","95","94","94","91","91","91","91","91","94","94","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"768","Togo","TGO","0.97835765","8.532096072","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"772","Tokelau","TKL","-171.8154473","-9.214545558","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"776","Tonga","TON","-175.1959991","-21.19511329","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","82","85","84","85","85","84","84","84","85","81","86","78","85","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"780","Trinidad and Tobago","TTO","-61.29389504","10.41877263","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","80","77","73","78","84","78","87","81","80","82","83","85","86","93","79","65",2016.0,"65","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"784","United Arab Emirates","ARE","53.98279159","23.43322219","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","92","92","92","92","92","94","93","93","92","93","94","95","96","98","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"788","Tunisia","TUN","9.572737411","34.11439971","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","99","98","99","99","99","98","98","99","97","98","96","96","98","95","98","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"792","Turkey","TUR","35.42890329","38.9899684","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","91","83","97","97","98","84","94","92","88","91","86","85","98","88","86","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"795","Turkmenistan","TKM","58.9787665","40.0912346","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","92","94","87","89","90","98","99","98","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"796","Turks and Caicos Islands","TCA","-71.745121","21.80780585","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"798","Tuvalu","TUV","178.6679611","-7.460048071","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","99","97","93","90","86","83","74","82","84","87","90","93","84","91","86","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"800","Uganda","UGA","32.39100438","1.279557331","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"804","Ukraine","UKR","31.40270802","49.00735945","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","98","98","99","97","96","98","96","95","68","41","56","54","54","57","57","31",2016.0,"31","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"807","The former Yugoslav Republic of Macedonia","MKD","21.7007909","41.60048068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","94","95","97","95","95","96","95","95","97","99","98","96","96","96","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"807","Macedonia, Republic of","MKD","21.7007909","41.60048068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"818","Egypt","EGY","29.77468534","26.57438204","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","99","96","97","96","97","97","97","96","96","97","97","92","96","93","92","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"826","United Kingdom of Great Britain and Northern Ireland","GBR","-2.23830539","53.27691757","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","76","74","74","77","76","75","75","74","75","79","84","85","87","88","89","91","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"826","United Kingdom","GBR","-2.23830539","53.27691757","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"831","Guernsey","GGY","-2.200712402","49.71561166","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"832","Jersey","JEY","-2.136773508","49.22353354","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"833","Isle of Man","IMN","-4.538190305","54.22880901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"834","Tanzania, United Republic of","TZA","34.80521182","-6.265332606","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"834","United Republic of Tanzania","TZA","34.80521182","-6.265332606","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","29","57","71",2016.0,"71","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"840","United States of America","USA","-99.13830311","39.5277871","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"850","United States Virgin Islands","VIR","-64.76960113","17.73297693","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"854","Burkina Faso","BFA","-1.742843829","12.27491081","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","17","50","50",2016.0,"50","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"858","Uruguay","URY","-56.01387025","-32.8002838","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","92","93","93","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"860","Uzbekistan","UZB","63.11944558","41.77560518","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","98","97","98","99","81","63","44","26","8","54","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"862","Venezuela (Bolivarian Republic of)","VEN","-66.15642084","7.121324748","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","6","31","26","33","38","50","52","53",2016.0,"53","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"876","Wallis and Futuna Islands","WLF","-176.2034788","-13.28471201","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"882","Samoa","WSM","-172.4430749","-13.61541469","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","84","65","45","26","6","36","46","14","30","50","52","72","63","48","44",2016.0,"44","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"887","Yemen","YEM","45.22389143","15.22242099","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","21","26","32","35","38","43","46","40","47","45","41","49",2016.0,"49","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"894","Zambia","ZMB","27.850329","-14.59701056","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_MCV2","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","33","47","58",2016.0,"58","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
